homovanillic acid has been researched along with Atherosclerotic Parkinsonism in 126 studies
Homovanillic Acid: A 3-O-methyl ETHER of (3,4-dihydroxyphenyl)acetic acid.
homovanillate : A hydroxy monocarboxylic acid anion which is obtained by deprotonation of the carboxy group of homovanillic acid.
homovanillic acid : A monocarboxylic acid that is the 3-O-methyl ether of (3,4-dihydroxyphenyl)acetic acid. It is a catecholamine metabolite.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Exposure to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) produces a syndrome that resembles Parkinson's disease." | 7.67 | The clinical syndrome of striatal dopamine deficiency. Parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). ( Burns, RS; Ebert, MH; Kopin, IJ; LeWitt, PA; Pakkenberg, H, 1985) |
| "Oral treatment with chrysin (10 mg/kg, 28 days), culminated with the prevention of these alterations occasioned by 6-OHDA." | 5.48 | Protective role of chrysin on 6-hydroxydopamine-induced neurodegeneration a mouse model of Parkinson's disease: Involvement of neuroinflammation and neurotrophins. ( Antunes, MS; Boeira, SP; Goes, ATR; Jesse, CR; Lobo Ladd, AAB; Lobo Ladd, FV; Luchese, C; Paroul, N, 2018) |
| " N-Methyl(R)salsolinol induced DNA damage to human neuroblastoma SH-SY5Y cells, which could be prevented by anti-oxidants and cycloheximide." | 3.70 | Oxidation of N-methyl(R)salsolinol: involvement to neurotoxicity and neuroprotection by endogenous catechol isoquinolines. ( Dostert, P; Kasamatsu, T; Maruyama, W; Naoi, M, 1998) |
| "Rapid-onset dystonia-parkinsonism (RDP) is a genetic movement disorder characterized by abrupt onset over hours to days of bradykinesia, postural instability, dysphagia, dysarthria, and severe dystonic spasms with decreased levels of the dopamine metabolite, homovanillic acid (HVA), in cerebrospinal fluid (CSF)." | 3.70 | PET imaging of the pre-synaptic dopamine uptake sites in rapid-onset dystonia-parkinsonism (RDP). ( Brashear, A; Farlow, MR; Hutchins, GD; Mulholland, GK; Siemers, ER; Zheng, QH, 1999) |
| "We investigated the effect of GM1 gangliosides on a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) animal model of Parkinson disease." | 3.68 | GM1 gangliosides alter acute MPTP-induced behavioral and neurochemical toxicity in mice. ( Albert, ML; Davoudi, H; Durso, R; Fazzini, E; Szabo, GK, 1990) |
| "Exposure to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) produces a syndrome that resembles Parkinson's disease." | 3.67 | The clinical syndrome of striatal dopamine deficiency. Parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). ( Burns, RS; Ebert, MH; Kopin, IJ; LeWitt, PA; Pakkenberg, H, 1985) |
| "26 patients with a paranoid-hallucinatory syndrome were treated with a fixed daily dose of haloperidol." | 3.65 | Clinical and biochemical parameters during neuroleptic treatment. I. Investigations with haloperidol. ( Ackenheil, M; Eben, E; Hippius, H; Rüther, E; Schilkrut, R, 1976) |
| "Prodipin does not cause an alteration in metabolite concentration in cases of interrupted therapy (group 1), but leads, in the case of continued therapy, to a 1." | 2.64 | CSF-changes of HVA and 5-HIAA during intermittent and continuous Parkinson therapy with particular regard to prodipin application. ( Oppel, F; Schulze, G, 1978) |
| "Oral treatment with chrysin (10 mg/kg, 28 days), culminated with the prevention of these alterations occasioned by 6-OHDA." | 1.48 | Protective role of chrysin on 6-hydroxydopamine-induced neurodegeneration a mouse model of Parkinson's disease: Involvement of neuroinflammation and neurotrophins. ( Antunes, MS; Boeira, SP; Goes, ATR; Jesse, CR; Lobo Ladd, AAB; Lobo Ladd, FV; Luchese, C; Paroul, N, 2018) |
| "Levodopa treatment in Parkinson's disease has been suggested to contribute to disease progression through free radical generation." | 1.30 | Time-dependent effects of levodopa on regional brain dopamine metabolism and lipid peroxidation. ( Arnold, LA; Camp, DM; Hyland, K; Juneau, PL; LeWitt, PA; Loeffler, DA, 1998) |
| "Homovanillic acid content was found to be significantly lower in patients with severe parkinsonism (motor score of UPDRS > 24), but not in patients with mild symptoms (motor score < or = 24)." | 1.29 | Cerebrospinal monoamine metabolites and amino acid content in patients with parkinsonian syndrome and rats lesioned with MPP+. ( Ambrosio, S; Bartrons, R; Bendahan, G; Calopa, M; Espino, A, 1994) |
| "Pretreatment with riluzole (8 mg kg-1, i." | 1.29 | Riluzole and experimental parkinsonism: partial antagonism of MPP(+)-induced increase in striatal extracellular dopamine in rats in vivo. ( Boireau, A; Doble, A; Dubédat, P; Meunier, M; Miquet, JM, 1994) |
| "The diagnosis of dopa-responsive dystonia should be considered in children with unexplained or atypical "cerebral palsy." | 1.29 | Dopa-responsive dystonia simulating cerebral palsy. ( Chutorian, AM; Levine, RA; Naini, AB; Nygaard, TG; Waran, SP, 1994) |
| "The behavioural, biochemical and morphological effects of a chronic administration of low doses of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) were studied in the common marmoset." | 1.29 | Chronic administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine to monkeys: behavioural, morphological and biochemical correlates. ( Albanese, A; Colosimo, C; Granata, R; Gregori, B; Piccardi, MP; Tonali, P, 1993) |
| "We describe two sporadic cases of dystonia-parkinsonism at different stages of disease progression." | 1.28 | Consideration on two cases of dystonia-parkinsonism. ( Balottin, U; Borgatti, R; Lanzi, G; Zambrino, CA, 1991) |
| "Treatment with bromocriptine (5 mg/kg) relieved the parkinsonian symptoms, but the efficacy of this treatment appeared to decrease slightly with time." | 1.28 | Effects of chronic treatment of MPTP monkeys with bromocriptine alone or in combination with SKF 38393. ( Bédard, PJ; Di Paolo, T; Rouillard, C, 1990) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 48 (38.10) | 18.7374 |
| 1990's | 52 (41.27) | 18.2507 |
| 2000's | 19 (15.08) | 29.6817 |
| 2010's | 7 (5.56) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Goes, ATR | 1 |
| Jesse, CR | 2 |
| Antunes, MS | 1 |
| Lobo Ladd, FV | 2 |
| Lobo Ladd, AAB | 2 |
| Luchese, C | 1 |
| Paroul, N | 1 |
| Boeira, SP | 2 |
| Del Fabbro, L | 1 |
| Rossito Goes, A | 1 |
| de Gomes, MG | 1 |
| Cattelan Souza, L | 1 |
| Nunes Arantes, RV | 1 |
| Reis Simionato, A | 1 |
| Oliveira, MS | 1 |
| Furian, AF | 1 |
| Herbert, MK | 1 |
| Kuiperij, H | 1 |
| Bloem, BR | 1 |
| Verbeek, MM | 1 |
| Yu, LH | 1 |
| Wei, HL | 1 |
| Bao, XQ | 1 |
| Zhang, D | 1 |
| Sun, H | 1 |
| Moraes, LS | 1 |
| Rohor, BZ | 1 |
| Areal, LB | 1 |
| Pereira, EV | 1 |
| Santos, AM | 1 |
| Facundo, VA | 1 |
| Santos, AR | 1 |
| Pires, RG | 1 |
| Martins-Silva, C | 1 |
| Joniec, I | 1 |
| Ciesielska, A | 1 |
| Kurkowska-Jastrzebska, I | 1 |
| Przybylkowski, A | 1 |
| Czlonkowska, A | 1 |
| Czlonkowski, A | 1 |
| Thakur, P | 1 |
| Nehru, B | 1 |
| Lin, L | 1 |
| Meng, T | 1 |
| Liu, T | 1 |
| Zheng, Z | 1 |
| McCormack, AL | 1 |
| Thiruchelvam, M | 1 |
| Manning-Bog, AB | 1 |
| Thiffault, C | 1 |
| Langston, JW | 2 |
| Cory-Slechta, DA | 1 |
| Di Monte, DA | 2 |
| Nichols, NF | 1 |
| Cimini, MG | 1 |
| Haas, JV | 1 |
| Staton, BA | 1 |
| Tedroff, J | 1 |
| Svensson, KA | 1 |
| Choi, JY | 1 |
| Park, CS | 1 |
| Kim, DJ | 1 |
| Cho, MH | 1 |
| Jin, BK | 1 |
| Pie, JE | 1 |
| Chung, WG | 1 |
| Bao, YC | 1 |
| Wang, H | 1 |
| Zhang, B | 1 |
| Kaur, D | 1 |
| Yantiri, F | 1 |
| Rajagopalan, S | 1 |
| Kumar, J | 1 |
| Mo, JQ | 1 |
| Boonplueang, R | 1 |
| Viswanath, V | 1 |
| Jacobs, R | 1 |
| Yang, L | 1 |
| Beal, MF | 3 |
| DiMonte, D | 1 |
| Volitaskis, I | 1 |
| Ellerby, L | 1 |
| Cherny, RA | 1 |
| Bush, AI | 1 |
| Andersen, JK | 2 |
| Wang, W | 1 |
| Zhao, DZ | 1 |
| Sun, XF | 1 |
| Gu, SD | 1 |
| Ahmad, AS | 1 |
| Ansari, MA | 1 |
| Ahmad, M | 1 |
| Saleem, S | 1 |
| Yousuf, S | 1 |
| Hoda, MN | 1 |
| Islam, F | 1 |
| Cannon, JR | 1 |
| Keep, RF | 1 |
| Schallert, T | 2 |
| Hua, Y | 1 |
| Richardson, RJ | 1 |
| Xi, G | 1 |
| Pérez, V | 1 |
| Sosti, V | 1 |
| Rubio, A | 1 |
| Barbanoj, M | 1 |
| Rodríguez-Alvarez, J | 1 |
| Kulisevsky, J | 1 |
| Bowers, MB | 4 |
| Heninger, GR | 1 |
| Melamed, E | 1 |
| Hefti, F | 1 |
| Wurtman, RJ | 1 |
| Arató, M | 1 |
| Bagdy, G | 1 |
| Perényi, A | 1 |
| Béla, A | 1 |
| Agnoli, A | 1 |
| Ruggieri, S | 1 |
| Falaschi, P | 1 |
| Baldassarre, M | 1 |
| D'Urso, R | 1 |
| Forchetti, C | 1 |
| Polleri, A | 1 |
| Vanderheyden, JE | 1 |
| Dekoninck, WJ | 1 |
| Lefèvre, A | 1 |
| Mendlewicz, J | 1 |
| Jenner, P | 4 |
| Rupniak, NM | 1 |
| Rose, S | 4 |
| Kelly, E | 2 |
| Kilpatrick, G | 2 |
| Lees, A | 1 |
| Marsden, CD | 5 |
| Cohen, G | 1 |
| Pasik, P | 2 |
| Cohen, B | 1 |
| Leist, A | 1 |
| Mytilineou, C | 1 |
| Yahr, MD | 2 |
| Kawai, K | 1 |
| Yanagi, T | 1 |
| Suzumura, A | 1 |
| Mokuno, K | 1 |
| Fornaguera, J | 1 |
| Schwarting, RK | 1 |
| Boix, F | 1 |
| Huston, JP | 1 |
| Altagracia, M | 2 |
| Rojas, P | 2 |
| Kravzov, J | 1 |
| Rios, C | 2 |
| Boireau, A | 3 |
| Dubédat, P | 2 |
| Bordier, F | 1 |
| Peny, C | 1 |
| Miquet, JM | 2 |
| Durand, G | 1 |
| Meunier, M | 2 |
| Doble, A | 2 |
| Espino, A | 2 |
| Ambrosio, S | 3 |
| Bartrons, R | 1 |
| Bendahan, G | 1 |
| Calopa, M | 2 |
| Nomoto, M | 3 |
| Irifune, M | 1 |
| Fukuzaki, K | 1 |
| Fukuda, T | 1 |
| Collier, TJ | 3 |
| Elsworth, JD | 6 |
| Taylor, JR | 4 |
| Sladek, JR | 6 |
| Roth, RH | 6 |
| Redmond, DE | 6 |
| Nygaard, TG | 1 |
| Waran, SP | 1 |
| Levine, RA | 1 |
| Naini, AB | 1 |
| Chutorian, AM | 1 |
| Sarre, S | 1 |
| De Klippel, N | 1 |
| Herregodts, P | 1 |
| Ebinger, G | 1 |
| Michotte, Y | 1 |
| Pérez-Otaño, I | 1 |
| Oset, C | 1 |
| Luquin, MR | 1 |
| Herrero, MT | 1 |
| Obeso, JA | 1 |
| Del Río, J | 1 |
| Albanese, A | 2 |
| Granata, R | 1 |
| Gregori, B | 1 |
| Piccardi, MP | 1 |
| Colosimo, C | 1 |
| Tonali, P | 1 |
| Schneider, JS | 3 |
| DiStefano, L | 2 |
| Buchet, JP | 1 |
| Magos, C | 1 |
| Roels, H | 1 |
| Ceulemans, E | 1 |
| Lauwerys, R | 1 |
| Gomez-Mancilla, B | 1 |
| Boucher, R | 3 |
| Gagnon, C | 1 |
| Di Paolo, T | 4 |
| Markstein, R | 1 |
| Bédard, PJ | 3 |
| Ortolà, J | 1 |
| Peres, J | 1 |
| Navarro, MA | 1 |
| Sardar, AM | 1 |
| Czudek, C | 1 |
| Reynolds, GP | 1 |
| Hantraye, P | 1 |
| Brouillet, E | 1 |
| Ferrante, R | 1 |
| Palfi, S | 1 |
| Dolan, R | 1 |
| Matthews, RT | 1 |
| Royland, JE | 1 |
| Jakowec, MW | 1 |
| Hattori, S | 1 |
| Hashitani, T | 2 |
| Matsui, N | 1 |
| Nishino, H | 2 |
| Gerlach, M | 1 |
| Gsell, W | 1 |
| Kornhuber, J | 1 |
| Jellinger, K | 1 |
| Krieger, V | 1 |
| Pantucek, F | 1 |
| Vock, R | 1 |
| Riederer, P | 2 |
| Laruelle, M | 1 |
| D'Souza, CD | 1 |
| Baldwin, RM | 1 |
| Abi-Dargham, A | 1 |
| Kanes, SJ | 1 |
| Fingado, CL | 1 |
| Seibyl, JP | 1 |
| Zoghbi, SS | 1 |
| Jatlow, P | 1 |
| Charney, DS | 1 |
| Innis, RB | 1 |
| Sullivan, AM | 1 |
| Opacka-Juffry, J | 1 |
| Hötten, G | 1 |
| Pohl, J | 1 |
| Blunt, SB | 1 |
| Sweet, RA | 1 |
| Pollock, BG | 1 |
| Mulsant, BH | 1 |
| Rosen, J | 1 |
| Lo, KH | 1 |
| Yao, JK | 1 |
| Henteleff, RA | 1 |
| Mazumdar, S | 1 |
| Matsubara, K | 1 |
| Gonda, T | 1 |
| Sawada, H | 1 |
| Uezono, T | 1 |
| Kobayashi, Y | 1 |
| Kawamura, T | 1 |
| Ohtaki, K | 1 |
| Kimura, K | 1 |
| Akaike, A | 1 |
| Naoi, M | 1 |
| Maruyama, W | 1 |
| Kasamatsu, T | 1 |
| Dostert, P | 1 |
| Mizukawa, K | 1 |
| Kumazaki, M | 1 |
| Teicher, MH | 1 |
| Andersen, SL | 1 |
| Campbell, A | 1 |
| Gelbard, HA | 1 |
| Baldessarini, RJ | 1 |
| Di Rocco, A | 1 |
| Brannan, T | 1 |
| Prikhojan, A | 1 |
| Cheng, FC | 1 |
| Ni, DR | 1 |
| Wu, MC | 1 |
| Kuo, JS | 1 |
| Chia, LG | 1 |
| Blanchet, PJ | 1 |
| Konitsiotis, S | 1 |
| Hyland, K | 2 |
| Arnold, LA | 2 |
| Pettigrew, KD | 1 |
| Chase, TN | 2 |
| Brashear, A | 1 |
| Mulholland, GK | 1 |
| Zheng, QH | 1 |
| Farlow, MR | 1 |
| Siemers, ER | 1 |
| Hutchins, GD | 1 |
| Loeffler, DA | 1 |
| LeWitt, PA | 2 |
| Juneau, PL | 1 |
| Camp, DM | 1 |
| Dethy, S | 1 |
| Laute, MA | 1 |
| Damhaut, P | 1 |
| Goldman, S | 1 |
| Kucherianu, VG | 1 |
| Kryzhanovskiĭ, GN | 1 |
| Kudrin, VS | 1 |
| Iurasov, VV | 1 |
| Nikushkin, EV | 1 |
| Zhigal'tsev, IV | 1 |
| Lawrence, MS | 1 |
| Fillebeen, C | 1 |
| Mitchell, V | 1 |
| Dexter, D | 1 |
| Benaissa, M | 1 |
| Beauvillain, J | 1 |
| Spik, G | 1 |
| Pierce, A | 1 |
| Ferger, B | 1 |
| Teismann, P | 1 |
| Earl, CD | 1 |
| Kuschinsky, K | 1 |
| Oertel, WH | 1 |
| Klivenyi, P | 1 |
| Andreassen, OA | 1 |
| Ferrante, RJ | 1 |
| Dedeoglu, A | 1 |
| Mueller, G | 1 |
| Lancelot, E | 1 |
| Bogdanov, M | 1 |
| Jiang, D | 1 |
| Bezard, E | 2 |
| Jaber, M | 1 |
| Gonon, F | 1 |
| Bloch, B | 1 |
| Gross, CE | 2 |
| Antkiewicz-Michaluk, L | 1 |
| Michaluk, J | 1 |
| Romańska, I | 1 |
| Papla, I | 1 |
| Vetulani, J | 1 |
| Tillerson, JL | 1 |
| Cohen, AD | 1 |
| Philhower, J | 1 |
| Miller, GW | 1 |
| Zigmond, MJ | 1 |
| Abe, K | 1 |
| Taguchi, K | 1 |
| Wasai, T | 1 |
| Ren, J | 1 |
| Utsunomiya, I | 1 |
| Shinohara, T | 1 |
| Miyatake, T | 1 |
| Sano, T | 1 |
| Dovero, S | 1 |
| Prunier, C | 1 |
| Ravenscroft, P | 1 |
| Chalon, S | 1 |
| Guilloteau, D | 1 |
| Crossman, AR | 1 |
| Bioulac, B | 1 |
| Brotchie, JM | 1 |
| Barthwal, MK | 1 |
| Srivastava, N | 1 |
| Dikshit, M | 1 |
| Kuriwaka, R | 1 |
| Mitsui, T | 1 |
| Fujiwara, S | 1 |
| Nishida, Y | 1 |
| Matsumoto, T | 1 |
| Miller, RJ | 1 |
| Hiley, CR | 1 |
| Curzon, G | 1 |
| Oppel, F | 1 |
| Schulze, G | 1 |
| Hoehn, MM | 1 |
| Crowley, TJ | 1 |
| Rutledge, CO | 1 |
| Rüther, E | 2 |
| Schilkrut, R | 2 |
| Ackenheil, M | 2 |
| Eben, E | 2 |
| Hippius, H | 2 |
| Gerlach, J | 1 |
| Thorsen, K | 1 |
| Fog, R | 1 |
| Doudet, DJ | 1 |
| Aigner, TG | 1 |
| McLellan, CA | 1 |
| Cohen, RM | 1 |
| Pope, A | 1 |
| Simpson, K | 1 |
| Taggart, J | 1 |
| Smith, MG | 1 |
| García Ruiz, PJ | 1 |
| Mena, MA | 1 |
| Peñafiel, N | 1 |
| De Yébenes, JG | 1 |
| Kravsov, J | 1 |
| Lisovoski, F | 1 |
| Haby, C | 1 |
| Borrelli, E | 1 |
| Schleef, C | 1 |
| Revel, MO | 1 |
| Hindelang, C | 1 |
| Zwiller, J | 1 |
| Skirboll, S | 1 |
| Wang, J | 1 |
| Mefford, I | 1 |
| Hsiao, J | 1 |
| Bankiewicz, KS | 2 |
| Pezzoli, G | 1 |
| Ricciardi, S | 1 |
| Masotto, C | 1 |
| Mariani, CB | 1 |
| Carenzi, A | 1 |
| Rausch, WD | 1 |
| Schallauer, E | 1 |
| Chan, WW | 1 |
| Weiser, M | 1 |
| Zambrino, CA | 1 |
| Balottin, U | 1 |
| Borgatti, R | 1 |
| Lanzi, G | 1 |
| Jolicoeur, FB | 1 |
| Rivest, R | 1 |
| St-Pierre, S | 1 |
| Drumheller, A | 1 |
| Bodis-Wollner, I | 1 |
| Chung, E | 1 |
| Ghilardi, MF | 1 |
| Glover, A | 1 |
| Onofrj, M | 1 |
| Samson, Y | 1 |
| Fazzini, E | 1 |
| Durso, R | 1 |
| Davoudi, H | 1 |
| Szabo, GK | 1 |
| Albert, ML | 1 |
| Rouillard, C | 1 |
| Deutch, AY | 3 |
| Bradbury, AJ | 1 |
| Costall, B | 1 |
| Jenner, PG | 1 |
| Kelly, ME | 1 |
| Naylor, RJ | 1 |
| Kish, SJ | 1 |
| Chang, LJ | 1 |
| Mirchandani, L | 1 |
| Shannak, K | 1 |
| Hornykiewicz, O | 2 |
| Bédard, P | 1 |
| Daigle, M | 1 |
| Saito, T | 1 |
| Ishizawa, H | 1 |
| Tsuchiya, F | 1 |
| Ozawa, H | 1 |
| Takahata, N | 1 |
| Johannessen, JN | 1 |
| Savitt, JM | 1 |
| Markey, CJ | 1 |
| Bacon, JP | 1 |
| Weisz, A | 1 |
| Hanselman, DS | 1 |
| Markey, SP | 1 |
| Yamamoto, M | 1 |
| Ujike, H | 1 |
| Ogawa, N | 1 |
| Teelken, AW | 1 |
| van den Berg, GA | 1 |
| Muskiet, FA | 1 |
| Staal-Schreinemachers, AL | 1 |
| Wolthers, BG | 1 |
| Lakke, JP | 1 |
| Ueki, A | 1 |
| Chong, PN | 1 |
| Chivers, JK | 1 |
| Jackson, EA | 1 |
| Gibb, WR | 1 |
| Burns, RS | 1 |
| Ebert, MH | 1 |
| Pakkenberg, H | 1 |
| Kopin, IJ | 3 |
| Russ, H | 1 |
| Henning, K | 1 |
| Eckhardt, H | 1 |
| Przuntek, H | 1 |
| Collins, MA | 2 |
| Neafsey, EJ | 2 |
| Camps, M | 1 |
| Ballarin, M | 1 |
| Reiriz, J | 1 |
| Blesa, R | 1 |
| Mahy, N | 1 |
| Young, AB | 1 |
| Haber, S | 1 |
| Ruberg, M | 1 |
| Javoy-Agid, F | 1 |
| Hirsch, E | 1 |
| Scatton, B | 1 |
| LHeureux, R | 1 |
| Hauw, JJ | 1 |
| Duyckaerts, C | 1 |
| Gray, F | 1 |
| Morel-Maroger, A | 1 |
| Rascol, A | 1 |
| Perry, TL | 2 |
| Jones, K | 2 |
| Hansen, S | 2 |
| Wall, RA | 1 |
| Hood, TW | 1 |
| Domino, EF | 1 |
| Greenberg, HS | 1 |
| Bankiewicz, K | 1 |
| Harvey-White, J | 1 |
| Falardeau, P | 1 |
| Bouchard, S | 1 |
| Pifl, C | 1 |
| Schingnitz, G | 1 |
| Schwartzman, RJ | 1 |
| Alexander, GM | 1 |
| Ferraro, TN | 1 |
| Grothusen, JR | 1 |
| Stahl, SM | 1 |
| Oldfield, EH | 1 |
| Chiueh, CC | 1 |
| Doppman, JL | 1 |
| Jacobowitz, DM | 1 |
| Zimmerman, DM | 1 |
| Cantrell, BE | 1 |
| Reel, JK | 1 |
| Hemrick-Luecke, SK | 1 |
| Fuller, RW | 1 |
| Cheng, BY | 1 |
| Hurley-Gius, K | 1 |
| Ung-Chhun, NA | 1 |
| Pronger, DA | 1 |
| Christensen, MA | 1 |
| Hurley-Gius, D | 1 |
| McLellan, DL | 1 |
| Chalmers, RJ | 1 |
| Johnson, RH | 1 |
| Messiha, FS | 1 |
| Turek, I | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Assessment of Carbidopa/l-Dopa and Carbidopa/l Dopa/Entacapone on Synaptic Dopamine in Parkinson's Patients: An Open-Label Feasibility/Pilot Study With [123I]-IBZM SPECT (DOPA-SYN)[NCT00200447] | Phase 2 | 3 participants (Actual) | Interventional | 2004-03-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for homovanillic acid and Atherosclerotic Parkinsonism
| Article | Year |
|---|---|
[Use of the probenecid test for the diagnosis and treatment of Parkinsonism. Review of the literature and personal experience (author's transl)].
Topics: Aged; Brain; Dopamine; Female; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; Middle Aged; Neu | 1980 |
Serotonergic mechanisms and extrapyramidal function in man.
Topics: 5-Hydroxytryptophan; Carbidopa; Cerebellar Diseases; Creutzfeldt-Jakob Syndrome; Down Syndrome; Extr | 1974 |
5 trials available for homovanillic acid and Atherosclerotic Parkinsonism
| Article | Year |
|---|---|
CSF somatostatin increase in patients with early parkinsonian syndrome.
Topics: Aged; Disease Progression; Female; Homovanillic Acid; Humans; Male; Middle Aged; Parkinson Disease, | 1995 |
Association of plasma homovanillic acid with behavioral symptoms in patients diagnosed with dementia: a preliminary report.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Antipsychotic Agents; Behavior; Dyskinesia, Drug-Induced | 1997 |
CSF-changes of HVA and 5-HIAA during intermittent and continuous Parkinson therapy with particular regard to prodipin application.
Topics: Aged; Antiparkinson Agents; Clinical Trials as Topic; Female; Homovanillic Acid; Humans; Hydroxyindo | 1978 |
Extrapyramidal reactions and amine metabolites in cerebrospinal fluid during haloperidol and clozapine treatment of schizophrenic patients.
Topics: Adult; Aged; Basal Ganglia Diseases; Clinical Trials as Topic; Clozapine; Dibenzazepines; Haloperido | 1975 |
A double-blind trial of tetrabenazine, thiopropazate, and placebo in patients with chorea.
Topics: Adult; Clinical Trials as Topic; Diseases in Twins; Dopamine; Drug Evaluation; Female; Homovanillic | 1974 |
119 other studies available for homovanillic acid and Atherosclerotic Parkinsonism
| Article | Year |
|---|---|
Protective role of chrysin on 6-hydroxydopamine-induced neurodegeneration a mouse model of Parkinson's disease: Involvement of neuroinflammation and neurotrophins.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Biomarkers; Dopamine; Flavonoids; Gene Expression Regulatio | 2018 |
Chrysin protects against behavioral, cognitive and neurochemical alterations in a 6-hydroxydopamine model of Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Brain; Cognition; Dopamine; Female; Flavonoids; Homovanilli | 2019 |
Levels of HVA, 5-HIAA, and MHPG in the CSF of vascular parkinsonism compared to Parkinson's disease and controls.
Topics: Aged; Cerebrovascular Disorders; Female; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; Male; | 2013 |
[Therapeutic effect of a natural squamosamide derivative FLZ on Parkinson's disease model mice induced by LPS plus MPTP].
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Acrylamides; Animals; | 2013 |
Medicinal plant Combretum leprosum mart ameliorates motor, biochemical and molecular alterations in a Parkinson's disease model induced by MPTP.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Combretum; Dopamine; Gene Expression Regulation; Homovanill | 2016 |
Age- and sex-differences in the nitric oxide synthase expression and dopamine concentration in the murine model of Parkinson's disease induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
Topics: 3,4-Dihydroxyphenylacetic Acid; Age Factors; Analysis of Variance; Animals; Blotting, Western; Chrom | 2009 |
Anti-inflammatory properties rather than anti-oxidant capability is the major mechanism of neuroprotection by sodium salicylate in a chronic rotenone model of Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Anti-Inflammatory Agents; Antioxidants; Brain; Catalase; Cy | 2013 |
Increased melatonin may play dual roles in the striata of a 6-hydroxydopamine model of Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Chromatography, High Pressure Liquid; Corpus Striatum; Data | 2013 |
Environmental risk factors and Parkinson's disease: selective degeneration of nigral dopaminergic neurons caused by the herbicide paraquat.
Topics: 1-Methyl-4-phenylpyridinium; 3,4-Dihydroxyphenylacetic Acid; Animals; Biomarkers; Dopamine; Environm | 2002 |
PNU-96391A (OSU6162) antagonizes the development of behavioral sensitization induced by dopamine agonists in a rat model for Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Behavior, Animal; Brain Chemistry; Dopamine; Dopamine Agonists; Dopam | 2002 |
Prevention of nitric oxide-mediated 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinson's disease in mice by tea phenolic epigallocatechin 3-gallate.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Blotting, Wes | 2002 |
[Preliminary experimental study on therapeutic mechanism of kangzhen zhijing capsule in treating Parkinson's disease].
Topics: Animals; Antiparkinson Agents; Dopamine; Drugs, Chinese Herbal; Glutathione Peroxidase; Homovanillic | 2001 |
Genetic or pharmacological iron chelation prevents MPTP-induced neurotoxicity in vivo: a novel therapy for Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Blotting, Wes | 2003 |
[The effect of shourong compound formula on levels of dopamine and its metabolites in brain of Parkinson's disease mice induced by reserpine].
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Benserazide; Brain; Dopamine; Drug Combinations; Drug Syner | 2002 |
Neuroprotection by crocetin in a hemi-parkinsonian rat model.
Topics: 3,4-Dihydroxyphenylacetic Acid; Analysis of Variance; Animals; Behavior, Animal; Carotenoids; Catala | 2005 |
Protease-activated receptor-1 mediates protection elicited by thrombin preconditioning in a rat 6-hydroxydopamine model of Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Behavior, Animal; Biotransformation; Catecholamines; Foreli | 2006 |
Modulation of the motor response to dopaminergic drugs in a parkinsonian model of combined dopaminergic and noradrenergic degeneration.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adenosine A2 Receptor Antagonists; Adrenergic Agents; Animals; Antip | 2007 |
Cerebrospinal fluid homovanillic acid patterns during neuroleptic treatment.
Topics: Adult; Antipsychotic Agents; Chlorpromazine; Female; Haloperidol; Homovanillic Acid; Humans; Male; P | 1981 |
Compensatory mechanisms in the nigrostriatal dopaminergic system in Parkinson's disease: studies in an animal model.
Topics: Animals; Corpus Striatum; Dopamine; Homovanillic Acid; Hydroxydopamines; Male; Oxidopamine; Parkinso | 1982 |
Family history and CSF homovanillic acid pattern during neuroleptic treatment.
Topics: Adult; Antipsychotic Agents; Basal Ganglia Diseases; Female; Homovanillic Acid; Hospitalization; Hos | 1984 |
Comparative neurochemical investigation of tardive dyskinesia and neuroleptic-induced chronic parkinsonism.
Topics: Adult; Antipsychotic Agents; Cyclic AMP; Dyskinesia, Drug-Induced; Homovanillic Acid; Humans; Male; | 1984 |
A neuropharmacological and neuroendocrine study on idiopathic and chronic pharmacological Parkinsonism.
Topics: Adult; Aged; Antipsychotic Agents; Chronic Disease; Circadian Rhythm; Homovanillic Acid; Humans; Hyd | 1980 |
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in the common marmoset.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Callitrichina | 1984 |
Pargyline and deprenyl prevent the neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Caudate Nucleus; Dopamine; Female; Homovanill | 1984 |
[Clinical characteristics of vascular parkinsonism].
Topics: Aged; Diagnosis, Differential; Electroencephalography; Female; Homovanillic Acid; Humans; Intracrani | 1983 |
Behavioral indices of moderate nigro-striatal 6-hydroxydopamine lesion: a preclinical Parkinson's model.
Topics: 3,4-Dihydroxyphenylacetic Acid; Amphetamine; Animals; Apomorphine; Corpus Striatum; Dopamine; Functi | 1993 |
Amantadine enhances dopamine and serotonin turnover in the MPTP model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amantadine; Animals; Brain Chemistry; Corpus Striatum; | 1993 |
Riluzole and experimental parkinsonism: antagonism of MPTP-induced decrease in central dopamine levels in mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Brain; Dopami | 1994 |
Cerebrospinal monoamine metabolites and amino acid content in patients with parkinsonian syndrome and rats lesioned with MPP+.
Topics: 1-Methyl-4-phenylpyridinium; Aged; Amino Acids; Animals; Biogenic Monoamines; Female; Homovanillic A | 1994 |
Effects of bifemelane on parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the common marmoset.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Antidepressiv | 1994 |
Peripheral nerve-dopamine neuron co-grafts in MPTP-treated monkeys: augmentation of tyrosine hydroxylase-positive fiber staining and dopamine content in host systems.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Chlorocebus aethiops; Dopamine; Fetal Tissue | 1994 |
Riluzole and experimental parkinsonism: partial antagonism of MPP(+)-induced increase in striatal extracellular dopamine in rats in vivo.
Topics: 1-Methyl-4-phenylpyridinium; 3,4-Dihydroxyphenylacetic Acid; Animals; Corpus Striatum; Dopamine; Exc | 1994 |
Dopa-responsive dystonia simulating cerebral palsy.
Topics: Adolescent; Adult; Biopterins; Carbidopa; Cerebral Palsy; Child; Diagnosis, Differential; Dose-Respo | 1994 |
Biotransformation of locally applied L-dopa in the corpus striatum of the hemi-parkinsonian rat studied with microdialysis.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Benserazide; Biotransformation; Corpus Striatum; Denervatio | 1994 |
MPTP-induced parkinsonism in primates: pattern of striatal dopamine loss following acute and chronic administration.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Corpus Striat | 1994 |
Chronic administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine to monkeys: behavioural, morphological and biochemical correlates.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Behavior, Ani | 1993 |
Oral administration of semisynthetic sphingolipids promotes recovery of striatal dopamine concentrations in a murine model of parkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Administration, Oral; | 1994 |
Urinary excretion of homovanillic acid in workers exposed to manganese.
Topics: Adult; Dust; Environmental Monitoring; Homovanillic Acid; Humans; Male; Manganese; Maximum Allowable | 1993 |
Effect of adding the D1 agonist CY 208-243 to chronic bromocriptine treatment. I: Evaluation of motor parameters in relation to striatal catecholamine content and dopamine receptors.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Antiparkinson Agents; Bromocriptine; Corpus Striatum; Dopam | 1993 |
Dopamine deficits in the brain: the neurochemical basis of parkinsonian symptoms in AIDS.
Topics: Acquired Immunodeficiency Syndrome; AIDS Dementia Complex; Case-Control Studies; Caudate Nucleus; Do | 1996 |
Inhibition of neuronal nitric oxide synthase prevents MPTP-induced parkinsonism in baboons.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Disease Model | 1996 |
Role of nitric oxide in methamphetamine neurotoxicity: protection by 7-nitroindazole, an inhibitor of neuronal nitric oxide synthase.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Body Temperature; Dopamine Agents; Enzyme Inhibitors; Homov | 1996 |
Dynamic regulation of striatal dopaminergic grafts during locomotor activity.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Cell Transplantation; Corpus Striatum; Dopamine; Extracellu | 1996 |
A post mortem study on neurochemical markers of dopaminergic, GABA-ergic and glutamatergic neurons in basal ganglia-thalamocortical circuits in Parkinson syndrome.
Topics: 3,4-Dihydroxyphenylacetic Acid; Aged; Aged, 80 and over; Basal Ganglia; Biomarkers; Cerebral Cortex; | 1996 |
Imaging D2 receptor occupancy by endogenous dopamine in humans.
Topics: Adult; Affect; alpha-Methyltyrosine; Animals; Benzamides; Brain; Dopamine; Enzyme Inhibitors; Homova | 1997 |
Growth/differentiation factor 5 protects nigrostriatal dopaminergic neurones in a rat model of Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Bone Morphogenetic Proteins; Corpus Striatum; Dopamine; Gro | 1997 |
Endogenously occurring beta-carboline induces parkinsonism in nonprimate animals: a possible causative protoxin in idiopathic Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Biogenic Monoamines; Brain; Carbolines; Cells, Cultured; Do | 1998 |
Oxidation of N-methyl(R)salsolinol: involvement to neurotoxicity and neuroprotection by endogenous catechol isoquinolines.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Antioxidants; Corpus Striatum; Cycloheximide; Disease Model | 1998 |
Dopamine metabolism in the striatum of hemiparkinsonian model rats with dopaminergic grafts.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Autoradiography; Brain Tissue Transplantation; Carrier Prot | 1998 |
Progressive accumbens degeneration after neonatal striatal 6-hydroxydopamine in rats.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Animals, Newborn; Caudate Nucleus; Chromatography, High Pre | 1998 |
Sertraline induced parkinsonism. A case report and an in-vivo study of the effect of sertraline on dopamine metabolism.
Topics: 1-Naphthylamine; 3,4-Dihydroxyphenylacetic Acid; Aged; Animals; Antidepressive Agents, Second-Genera | 1998 |
Glial cell line-derived neurotrophic factor protects against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced neurotoxicity in C57BL/6 mice.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Behavior, Animal; Brain Chemistry; Disease Models, Animal; | 1998 |
Chronic exposure to MPTP as a primate model of progressive parkinsonism: a pilot study with a free radical scavenger.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Biomarkers; B | 1998 |
PET imaging of the pre-synaptic dopamine uptake sites in rapid-onset dystonia-parkinsonism (RDP).
Topics: Adult; Aged; Brain Mapping; Carbon Radioisotopes; Cocaine; Corpus Striatum; Diagnosis, Differential; | 1999 |
Time-dependent effects of levodopa on regional brain dopamine metabolism and lipid peroxidation.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Brain; Cerebellum; Corpus Striatum; Dopamine; Dopamine Agen | 1998 |
Pergolide potentiates L-DOPA-induced dopamine release in rat striatum after lesioning with 6-hydroxydopamine.
Topics: 3,4-Dihydroxyphenylacetic Acid; Amphetamine; Animals; Disease Models, Animal; Dopamine; Dopamine Ago | 1999 |
[Effect of acidic fibroblast growth factor on experimental parkinsonism and levels of dopamine and its metabolites in the striatum of mice of various ages].
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Administration, Intran | 1999 |
Spontaneous blink rates correlate with dopamine levels in the caudate nucleus of MPTP-treated monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Blinking; Caudate Nucleus; Chlorocebus aethio | 1999 |
Lactoferrin is synthesized by mouse brain tissue and its expression is enhanced after MPTP treatment.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Catalase; Cor | 1999 |
Salicylate protects against MPTP-induced impairments in dopaminergic neurotransmission at the striatal and nigral level in mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Anti-Inflamma | 1999 |
Mice deficient in cellular glutathione peroxidase show increased vulnerability to malonate, 3-nitropropionic acid, and 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Brain Chemist | 2000 |
Striatal dopaminergic correlates of stable parkinsonism and degree of recovery in old-world primates one year after MPTP treatment.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Chlorocebus aethiops; Disea | 2000 |
Adaptive changes in the nigrostriatal pathway in response to increased 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurodegeneration in the mouse.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Carrier Proteins; Cell Count; Corpus Striatum; Disease Mode | 2000 |
Antidopaminergic effects of 1,2,3,4-tetrahydroisoquinoline and salsolinol.
Topics: Animals; Antiparkinson Agents; Apomorphine; Binding, Competitive; Brain Chemistry; Catalepsy; Dopami | 2000 |
Forced limb-use effects on the behavioral and neurochemical effects of 6-hydroxydopamine.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Apomorphine; Behavior, Animal; Body Temperature; Casts, Sur | 2001 |
Biochemical and pathological study of endogenous 1-benzyl-1,2,3,4-tetrahydroisoquinoline-induced parkinsonism in the mouse.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Dopamine; Dru | 2001 |
Relationship between the appearance of symptoms and the level of nigrostriatal degeneration in a progressive 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Autoradiograp | 2001 |
Role of nitric oxide in a progressive neurodegeneration model of Parkinson's disease in the rat.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adrenergic Agents; Animals; Corpus Striatum; Disease Models, Animal; | 2001 |
Loss of postural reflexes in long-term occupational solvent exposure.
Topics: Adult; Air Pollutants, Occupational; Atrophy; Cerebellum; Homovanillic Acid; Humans; Magnetic Resona | 2002 |
Anti-dopaminergic and anti-muscarinic effects of dibenzodiazepines: relationship to drug induced Parkinsonism.
Topics: Adenylyl Cyclases; Animals; Cerebral Cortex; Choline; Clozapine; Corpus Striatum; Dibenzazepines; Di | 1976 |
CSF homovanillic acid: an index of dopaminergic activity.
Topics: Antiparkinson Agents; Brain; Dopamine; Hepatic Encephalopathy; Homovanillic Acid; Humans; Huntington | 1975 |
The Parkinsonian syndrome and its dopamine correlates.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adult; Aged; Dopamine; Extrapyramidal Tracts; Female; Homovanillic A | 1977 |
Clinical and biochemical parameters during neuroleptic treatment. I. Investigations with haloperidol.
Topics: Adult; Female; Hallucinations; Haloperidol; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; Mal | 1976 |
Clinical and biochemical parameters during neuroleptic treatment. II. Antipsychotic effect of haloperidol in patients with chronic organic brain damage.
Topics: Adult; Aged; Brain Damage, Chronic; Depression; Female; Hallucinations; Haloperidol; Homovanillic Ac | 1976 |
Positron emission tomography with 18F-dopa: interpretation and biological correlates in nonhuman primates.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Carbidopa; Cerebral Cortex; Corpus Striatum; | 1992 |
Recovery from experimental parkinsonism in primates with GM1 ganglioside treatment.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Corpus Striat | 1992 |
Cinnarizine-induced parkinsonism in primates.
Topics: Animals; Biogenic Monoamines; Cinnarizine; Disease Models, Animal; Dopamine; Haplorhini; Homovanilli | 1992 |
Partially protective effect of amantadine in the MPTP model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amantadine; Animals; Corpus Striatum; Dopamine; Homova | 1992 |
Induction of D2 dopamine receptor mRNA synthesis in a 6-hydroxydopamine parkinsonian rat model.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Apomorphine; Blotting, Northern; Corpus Striatum; Dopamine; | 1992 |
MPTP-induced parkinsonism: acceleration of biochemical and behavioral recovery by GM1 ganglioside treatment.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Behavior, Animal; Cats; Caudate Nucleus; Dopamine; Female; | 1992 |
In vivo changes of catecholamines in hemiparkinsonian monkeys measured by microdialysis.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Catecholamine | 1990 |
n-hexane induces parkinsonism in rodents.
Topics: Animals; Corpus Striatum; Dopamine; Hexanes; Hexanones; Homovanillic Acid; Hydroxyindoleacetic Acid; | 1990 |
Effects of L-deprenyl and amantadine in an MPTP-model of parkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Amantadine; Animals; C | 1990 |
Consideration on two cases of dystonia-parkinsonism.
Topics: Carbidopa; Child; Dystonia; Female; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; Levodopa; M | 1991 |
Antiparkinson-like effects of neurotensin in 6-hydroxydopamine lesioned rats.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Antiparkinson Agents; Behavior, Animal; Brain Chemistry; Ca | 1991 |
Acetyl-levo-carnitine protects against MPTP-induced parkinsonism in primates.
Topics: Acetylcarnitine; Animals; Carbidopa; Caudate Nucleus; Electroretinography; Female; Homovanillic Acid | 1991 |
GM1 gangliosides alter acute MPTP-induced behavioral and neurochemical toxicity in mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Behavior, Ani | 1990 |
Effects of chronic treatment of MPTP monkeys with bromocriptine alone or in combination with SKF 38393.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzaze | 1990 |
MPTP-induced parkinsonism: relative changes in dopamine concentration in subregions of substantia nigra, ventral tegmental area and retrorubral field of symptomatic and asymptomatic vervet monkeys.
Topics: Animals; Cercopithecus; Dopamine; Homovanillic Acid; Male; MPTP Poisoning; Parkinson Disease, Second | 1990 |
The neurotoxic actions of 1-methyl-4-phenylpyridine (MPP+) are not prevented by deprenyl treatment.
Topics: 1-Methyl-4-phenylpyridinium; 3,4-Dihydroxyphenylacetic Acid; Animals; Corpus Striatum; Female; Homov | 1985 |
Progressive supranuclear palsy: relationship between extrapyramidal disturbances, dementia, and brain neurotransmitter markers.
Topics: Aged; Aspartic Acid; Basal Ganglia Diseases; Brain; Bulbar Palsy, Progressive; Choline O-Acetyltrans | 1985 |
Long-term effects of MPTP on central and peripheral catecholamine and indoleamine concentrations in monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Biogenic Amin | 1986 |
Neurochemical findings in the cerebrospinal fluid of schizophrenic patients with tardive dyskinesia and neuroleptic-induced parkinsonism.
Topics: Adult; Aged; Antipsychotic Agents; Catecholamines; Dopamine; Dyskinesia, Drug-Induced; Epinephrine; | 1986 |
The development of amine substituted analogues of MPTP as unique tools for the study of MPTP toxicity and Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Amines; Animals; Brain | 1987 |
Metoclopramide-induced parkinsonism.
Topics: Aged; Aged, 80 and over; Anorexia; Gastritis; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; M | 1987 |
Catecholamine metabolism during additional administration of DL-threo-3,4-dihydroxyphenylserine to patients with Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Aged; Catecholamines; Dopamine; Droxidopa; Female; Homovanillic Acid | 1989 |
Increased caudate dopamine turnover may contribute to the recovery of motor function in marmosets treated with the dopaminergic neurotoxin MPTP.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Callitrichina | 1989 |
Further treatment with MPTP does not produce parkinsonism in marmosets showing behavioural recovery from motor deficits induced by an earlier exposure to the toxin.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Autoradiograp | 1989 |
Treatment with a selective MAO B inhibitor prevents loss of dopamine in the nucleus accumbens of MPTP-treated common marmosets.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Allylamine; Animals; B | 1989 |
The clinical syndrome of striatal dopamine deficiency. Parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adult; Corpus Striatum; Dopamine; Female; Homovanillic | 1985 |
The influence of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine on the levels of dopamine, serotonin and their metabolites in the caudate nucleus of the rat.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Caudate Nucle | 1985 |
Beta-carboline analogues of N-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP): endogenous factors underlying idiopathic parkinsonism?
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Aotus trivirg | 1985 |
Symptomatic and asymptomatic 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated primates: biochemical changes in striatal regions.
Topics: Animals; Cercopithecus; Corpus Striatum; Dopamine; Homovanillic Acid; Male; MPTP Poisoning; Parkinso | 1989 |
Dopamine D1 and D2 receptors visualized in MPTP treated C57 mice by in vitro autoradiography: lack of evidence of receptor modifications in parkinsonian mice.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Autoradiography; Benzazepines; Brain; Dopamine; Homovanilli | 1989 |
Cerebrospinal fluid homovanillic acid and hypokinetic side effects of neuroleptics.
Topics: Acetylcholine; Adolescent; Adult; Antipsychotic Agents; Catatonia; Chlorpromazine; Dopamine; Female; | 1985 |
Progressive supranuclear palsy: postmortem chemical analysis.
Topics: Basal Ganglia; Brain; Bulbar Palsy, Progressive; Choline O-Acetyltransferase; Dopamine; gamma-Aminob | 1985 |
Fetal neuronal grafts in monkeys given methylphenyltetrahydropyridine.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Chlorocebus aethiops; Disease Models, Animal; | 1986 |
Dopaminergic and cholinergic lesions in progressive supranuclear palsy.
Topics: Aged; Brain; Bulbar Palsy, Progressive; Choline O-Acetyltransferase; Corpus Striatum; Dopamine; Fema | 1985 |
2-Phenylpyridine and 3-phenylpyridine, constituents of tea, are unlikely to cause idiopathic Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Corpus Striatum; Dopamine; Female; Homovanillic Acid; Mice; | 1988 |
Possible treatment of Parkinson's disease with intrathecal medication in the MPTP model.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Homovanillic | 1988 |
Effect of MPTP-induced parkinsonism in monkeys on the urinary excretion of HVA and MHPG during debrisoquin administration.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Creatinine; Debrisoquin; Female; Glycols; Hom | 1988 |
Behavioral and biochemical effect of chronic treatment with D-1 and/or D-2 dopamine agonists in MPTP monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzaze | 1988 |
The neurotoxin MPTP does not reproduce in the rhesus monkey the interregional pattern of striatal dopamine loss typical of human idiopathic Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Corpus Striatum; Female; Homovanillic Acid; H | 1988 |
Cerebral metabolism of parkinsonian primates 21 days after MPTP.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Autoradiography; Brain; Corpus Striatum; Dopa | 1988 |
Hemiparkinsonism in monkeys after unilateral internal carotid artery infusion of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Apomorphine; Brain; Brain Chemistry; Carbidop | 1986 |
Characterization of the neurotoxic potential of m-methoxy-MPTP and the use of its N-ethyl analogue as a means of avoiding exposure to a possible Parkinsonism-causing agent.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Brain; Corpus | 1986 |
Endogenous analogs of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: indoleamine derived tetrahydro-beta-carbolines as potential causative factors in Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Aotus trivirg | 1987 |
Exposure to cigarette smoke does not decrease the neurotoxicity of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Corpus Striat | 1987 |
Decreased dopamine and homovanillic acid excretion in a case with chlorpromazine-induced Parkinsonism.
Topics: Chlorpromazine; Dopamine; Homovanillic Acid; Humans; Male; Parkinson Disease; Parkinson Disease, Sec | 1973 |